Announcement

Collapse
No announcement yet.

Japan: Measures against flu needed / Govt urged to set up framework to fight potential emerging influenza outbreak

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Japan: Measures against flu needed / Govt urged to set up framework to fight potential emerging influenza outbreak

    Measures against flu needed / Govt urged to set up framework to fight new influenza outbreak

    Masae Honma / Yomiuri Shimbun Staff Writer

    The government has finally started drawing up measures to prepare for a possible outbreak of a new strain of pandemic influenza, including the inoculation of 6,000 medical practitioners and quarantine officers with pre-pandemic influenza vaccine by the end of this fiscal year.

    However, concrete plans to deal with such an outbreak are underdeveloped. The government needs to establish a framework for containing a possible pandemic as a matter of urgency.

    At a meeting of Health, Labor and Welfare Ministry experts held April 16 to discuss measures for tackling an outbreak, Nobuhiko Okabe, chair of the meeting and director of the Infectious Disease Surveillance Center--an arm of the National Institute of Infectious Diseases--stressed the importance of inoculation.

    "A new influenza virus is waiting to emerge. We need to do everything we can before the outbreak," Okabe said.

    The pre-pandemic influenza vaccine contain antigens that correspond to the H5N1 influenza virus, a type of avian flu that has spread from birds to humans in countries including China and Indonesia. According to the World Health Organization, avian flu had killed 240 people worldwide as of last Thursday.

    The vaccine would not offer full protection against the new envisioned influenza virus because the new strain likely would develop via the mutation of the avian flu virus. However, it is expected the vaccine will at least partially block infection and stop serious symptoms from developing while vaccines that contain antigens corresponding to the new virus are being created following a possible outbreak.

    The United States and advanced countries in Europe are currently storing pre-pandemic vaccines. Switzerland already has prepared enough vaccine to inoculate all its citizens.

    If the government goes ahead with its plans, Japan would be the first country to administer the vaccine to a large number of people. The government is worried about the possibility of another avian flu outbreak centering on Asia. According to the government's estimate, a new influenza strain could enter Japan within two weeks after the virus is confirmed in Asia. However, experts say it could arrive much earlier. The government believes it would be too late to carry out a vaccination program after a new virus has been confirmed.

    However, as some of the 20 million doses of vaccine currently in stock are due to expire next year, the government has decided to initially inoculate about 6,000 people who have the highest chance of coming into contact with carriers of a new influenza strain. Quarantine officers and doctors and nurses working at designated hospitals for infectious diseases would be among the first wave of inoculees.

    The government has shown a willingness to tackle this type of influenza entering the country. However, there are several possible problems associated with its plans, including whether doctors and nurses would cooperate with the inoculation program.

    The vaccination has risks. Okabe explained that one of the objectives of the initial vaccinations would be to confirm the vaccine's degree of safety. No serious side effects other than fever were confirmed during a clinical trial conducted on about 1,000 people, but rare side effects expected to occur in one in 10,000 people have not been examined yet. With measles vaccinations, serious side effects such as encephalitis occur once in every 1 million to 1.5 million cases.

    Moreover, even if the people accept the risks associated with the vaccination, the effectiveness of the vaccine against the possible new influenza strain is unclear. For the second wave of inoculations, the government is considering vaccinating the about 10 million people who support the public infrastructure, such as gas, electricity and transportation workers. Ordinary citizens would be at the end of the queue for the vaccine. To ensure cooperation from the public, statistically derived detailed information must be provided on the benefits and risks involved.

    In addition to the inoculation, the government this month announced measures to block new types of influenza from entering Japan, such as by restricting the number of foreigners entering Japan from countries where such diseases are known to exist, and prohibiting Japanese infected with a new type of flu from returning to Japan. However, whether such steps would prove effective is unknown.

    Measures to deal with a new influenza strain once it has entered the country are lagging behind those of other advanced nations.

    Microbiologist Prof. Hitoshi Oshitani of Tohoku University's Faculty of Medicine told the meeting, "We need to discuss measures to minimize the spread of a new influenza strain after it has entered the country."

    However, the details of such measures--including how to prioritize vaccinations and secure an adequate number of medical practitioners when they might be susceptible to infection--are not yet available.

    Experts point out it is difficult to prevent new influenza strains from reaching and spreading across Japan unless such measures are implemented rapidly.

    Local governments and private companies are currently at a loss as to what measures to take against a possible pandemic of a new influenza strain. The government needs to draw up a framework that includes a vaccination timetable and a prioritization list as soon as possible, to allow local governments and companies to put in place concrete measures to tackle a possible pandemic.
    (Apr. 24, 2008)

  • #2
    Re: Japan: Measures against flu needed / Govt urged to set up framework to fight potential emerging influenza outbreak

    "However, as some of the 20 million doses of vaccine currently in stock are due to expire next year"

    Seems that the idea (wroted FT posts) of some vaccine producers to produce a longer shelf life vaccine by divide it in 2 separate components (adjuvant and the rest) which will be combined together only previously the vaccinations, was good and necessary.

    Comment


    • #3
      Re: Japan: Measures against flu needed / Govt urged to set up framework to fight potential emerging influenza outbreak

      [FROM ECDC INFLUENZA NEWS - IOH]

      Japanese Ministry of Health to initiate large vaccination trial of human H5N1 avian influenza vaccine in health care and emergency response workers.

      ECDC is grateful to the WHO Collaborating Centre in Japan for helping compile this particular report.

      The Japanese Government has announced that it will organise a large scale clinical research trial to assess the efficacy and safety of stockpiled human H5N1 vaccines (sometimes called pre-pandemic vaccines). Currently 20 million doses of H5N1 vaccine are held by the Japanese Government.

      It is planned to vaccinate 6,400 volunteers from quarantine offices, health care workers and emergence response workers with vaccines with alum adjuvant prepared from Anhui and Indonesia H5N1 strains. The trial has several aims:

      * To assess the safety of vaccines, particularly the safety of inoculating the same people with two different H5N1 strains.

      * To assess cross-reactive immunity between the vaccine strains retained in the Japanese stockpile and other clade and subclade viruses

      * to obtain information about priming and boosting effect with homologous and heterologous vaccines.
      * To obtain data on the duration of immunity induced by each vaccine.

      It is been suggested that if the safety and effectiveness of these vaccines are confirmed in this large trial, the Japanese Government may then consider expanding pre-pandemic vaccination to wider prioritized target groups covering up to 10 million people.

      ECDC Comment (24/04/08):
      The reasons for the trial are to some extent pragmatic, in that the first batches of stockpiled human H5N1 vaccines in Japan are due to expire in the near future, and hence it as judged to be more appropriate to use these vaccines rather than discard them.

      When coming to the final decision, the Japanese Government also considered that it would take 6 weeks to develop vaccines from bulk stockpiles, and a further 3-4 weeks for immunised individuals to develop full immunity.

      In a pandemic, a delay of 10 weeks before a pre-pandemic vaccine is able to provide its protection to key workers was not optimal. Hence trialling the use of human A/H5N1 vaccines now in such key workers will give policy makers good data set and a ?proof of concept? to extend human A/H5N1 vaccines to prioritized target groups in the wider population.

      An important general point when considering H5N1 vaccines is that it is not certain that the next pandemic will be caused by an H5 virus subtype.

      Only if there is reasonable cross reactivity between the vaccine strain and the pandemic virus will such vaccines offer any protection for those that have been immunised.

      However, there will be significant delay in obtaining pandemic strain specific vaccines, and as reported by the Japanese even the time taken to develop and administer vaccines from currently available strains can be significant.

      Hence there remains difficult decisions for public health authorities about the possible use of available vaccines in the current pre-pandemic phase, notably ?if? to use them, and also ?when? to use them (1-3).

      The information from the Japanese work will become available in the spring of 2009, and will provide important data for assisting European Countries in developing their policies with regards to these vaccines.

      Some European have already purchased the vaccines and others are considering whether to do so. In 2007 ECDC assembled two expert panels to review the scientific and public health aspects of these vaccines and their reports were published. (1-2), together with an accompanying Eurosurveillance article (3).

      This is a developing field. ECDC and WHO (which held a meeting drawing in part on the ECDC reports) will need to decide when to return to this topic perhaps when the Japanese data become available.

      1) ECDC Technical report: Conclusion of the Expert Advisory Groups on human H5N1 vaccines- Scientific Questions. Stockholm, August 2007.
      2) ECDC Technical report: Conclusion of the Expert Advisory Groups on human H5N1 vaccines- Public Health and Operational Questions. Stockholm, August 2007
      3) Influenza team (ECDC). Human influenza A/H5N1 (?pre-pandemic?) vaccines: informing policy development in Europe. Euro Surveill. 2007;12(38):pii=3272. Available online
      -------

      Comment


      • #4
        Re: Japan: Measures against flu needed / Govt urged to set up framework to fight potential emerging influenza outbreak

        ""It is planned to vaccinate 6,400 volunteers from quarantine offices, health care workers and emergence response workers with vaccines with alum adjuvant prepared from Anhui and Indonesia H5N1 strains.""



        Human H5N1 in Anhui China Has HA Q226R

        Recombinomics Commentary
        April 3, 2006

        China has release three H5N1 HA human sequences, A/Anhui/1/2005(H5N1), A/Anhui/2/2005(H5N1). A/Guangxi/1/2005(H5N1). The isolates appear to be linked to the case of the pregnant woman from Anhui based on the title of the submissions. WHO reports describe a 35F from Anhui (who developed symptoms November 11, 2005, was hospitalized on November 15, and died on November 25) as well as a 24F from Anhui who was hospitalized at about the same time, as well as a 10F from Guangxi who developed symptoms on November 23, 2005.

        All three of these isolates were most closely related to an H5N1 isolate from Fujian province, A/duck/Fujian/1734/05(H5N1) and contain a number of distinctive polymorphisms including an HA cleavage site missing a lysine (RERRRKR), a glycosylation site due to A160T, changes near the receptor binding domain (P185S, R193K) and a change just upstream from the HA cleavage site at Q315L. The notable changes as well as many more suggest that pandemic vaccines directed against the strain from Vietnam or Indonesia would have limited protection against the three isolates from China.

        Moreover, A/Anhui/2/2005(H5N1) also has a change within the receptor binding domain due to A741G creating Q226R. Donor sequences for this change are found in non-human H3 sequences, including swine. Changes in the receptor binding domain are cause for concern and the changes could increase affinity for human receptors.

        Earlier isolates from Hong Kong from two family members who had visited Fujian province had another change in the adjacent position in the receptor binding domain, S227N, which was associated with increased affinity for human receptors and was also found in the index case in Turkey.

        The changes in H5N1 in human isolates in China clearly suggest the pandemic vaccine program may not be directed against a sufficient number of targets. The change in the receptor binding domain also highlights the easy with which such changes can happen, which could significantly increase the efficiency of transmission to humans.

        More sequences from human H5N1 cases in China would be useful.

        The following isolates have donor sequences in HA for Q226R.

        DQ371929 A/Anhui/2/2005 2005 H5N1
        DQ447186 A/swine/Taiwan/0408/2004 2004 H3N1
        AY619977 A/Swine/Ontario/42729A/01 2001 H3N3
        AY619969 A/Swine/Ontario/K01477/01 2001 H3N3
        AY633172 A/mallard/Alberta/199/99 1999 H3N6
        AY633372 A/pintail/Alberta/37/99 1999 H3N8
        L31949 A/Seal/Massachusetts/3911/92 1992 H3N3
        L32024 A/Seal/Massachusetts/3984/92 1992 H3N3
        CY006035 A/duck/New Zealand/38/1984 1984 H3N8
        AJ252132 A/swine/Potsdam/35/82 1982 H3N2

        Media Sources

        Comment


        • #5
          Re: Japan: Measures against flu needed / Govt urged to set up framework to fight potential emerging influenza outbreak

          Source: http://search.japantimes.co.jp/cgi-b...0080511a1.html
          Sunday, May 11, 2008

          EDITORIAL
          Coping with new strains of flu

          The Diet has passed revisions to the Infectious Disease Law and the Quarantine Law to effectively cope with a possible outbreak of new types of influenza. There is fear that deadly new types of influenza will emerge, since the H5N1 bird flu is spreading mainly in Southeast Asia and bird-to-human infection is increasing. If a bird flu virus mutates into one capable of human-to-human transmission, a large number of people are expected to die. The government estimates that a new type of flu with the same lethality rate as the 1918 Spanish flu could kill up to 640,000 Japanese.

          The law revisions will enable the government to segregate or forcibly hospitalize those who have developed symptoms of, are infected with, or are suspected of being infected with new types of flu. The government can prohibit such people from going to work.

          The government has also decided to conduct a clinical test this fiscal year in which some 6,000 doctors, quarantine inspectors, other medical and health professionals and immigration and customs officials will be inoculated with stockpiled "pre-pandemic" vaccine based on the H5N1 virus strain. It also will inoculate 120 children at least 6 months old and younger than 20 with the same vaccine. If the vaccination proves safe and effective, it plans to vaccinate 10 million people whose work is related to maintaining basic functions of society.

          The government, which has stockpiled a solution to produce pre-pandemic vaccine for 20 million people, plans to increase the stock to cover an additional 10 million people. It also plans to develop new technology to shorten from 1 1/2 years to six months the time to produce vaccine based on new virus strains.

          The use of the pre-pandemic vaccine before an outbreak of a new flu type is the first in the world. But the government must carefully execute the clinical test inoculations, especially for children. Dangers from side effects and aftereffects cannot be ruled out. The government also should consider effective measures against ordinary flu.

          Comment

          Working...
          X